Many of the experimental models of drug resistance rely on the development of resistance in vitro through growth of cells in drug-containing medium or in vivo through treatment of mice bearing ascites or subcutaneous tumours. While these models have the advantage that they produce sensitive and resistant sublines of the same cell line the general relevance of these models to clinical drug resistance is yet to be established. In particular, using these models, cross-resistance between anthracyclines, vinca alkaloids, VP16 and antibiotics is often observed (see Discussion). Since certain therapeutic strategies (e.g. the use of calcium antagonists; Tsuruo et al., 1981) have been shown to be effective in overcoming this resistance, the demonstration of a similar pattern of cross resistance in human tumour cell lines which have not been exposed to cytotoxic drugs in the laboratory would suggest that clinical trials employing similar strategies might be justified.
In this paper we use the term inherent resistance to describe resistance that has not been induced by exposure to cytotoxic drugs in experimental animals or in vitro.
For the drugs adriamycin (ADR) and vincristine (VC) Tsuruo et al. (1983a,b) have shown that the inherent resistance of both human haemopoietic and murine tumour lines can be circumvented by the calcium antagonist verapamil. Merry et al. (1986a) have also shown that inherent resistance to ADR in human glioma cell lines can be overcome by verapamil and that this is associated with increased intracellular drug levels. Similar results have also been obtained by Rogan et al. (1984) using human ovarian cancer cell lines.
In this paper we present data on the cross-sensitivity of a panel of human non-small cell lung cancer cell lines to some commonly-used cytotoxic drugs. We also report data on the use of verapamil as a means of circumventing resistance in human lung cancer which suggest that clinical studies employing this approach may be justified.
Materials and methods
Seven established human non-small cell lung cancer cell lines were used in this study. Their sources, pathological details and (where available) the treatment undergone by the patient prior to the establishment of the cell line are shown in 
Cytotoxicity assay
The method used has been described previously (Merry et al., 1984 Drug uptake assaY' The method used has been described previously (Merry et al., 1986a Verapamil at 2.2pM increased VP16 cytotoxicity for both WIL (4.0-fold change in ID50) and A549 (3.3-fold change in ID50) i.e. 32% (WIL) and 62% (A549) of that produced by 6.6 IIM verapamil. In no other case was an increase in sensitivity noted (data not shown).
Drug uptake experiments
In preliminary experiments with each of the drug combinations and using identical conditions to those of the drug uptake studies, cell viability (as determined by trypan blue exclusion) and cell loss from the monolayer (as determined by counting cell number in representative microscope fields) were reduced by <5% for both A549 and SK-MES-1 (data not shown).
In the drug uptake studies unbound drug was determined as that released during a 30 min incubation in glucosecontaining medium. In control experiments (for each drug or drug combination) release of radioactivity under these conditions was shown to be initially rapid followed by a slower (apparently linear) release (data not shown). The initial phase of drug release reached completion at 30min. Figure I shows the effect of 6.6/tiM verapamil on the uptake of VC by SK-MES-1. The general shape of the curves are typical of those obtained for all three drugs (ADR, VC and VP16) in both cell lines (A549 and SK-MES-1). In all cases uptake of unbound drug was close to plateau levels at 30 min (both in the absence and presence of verapamil), while levels of bound drug in the presence of verapamil were apparently still rising at 90min. The data of the drug uptake experiments are shown in Table V . For ADR, VC and VP16 respectively A549 is 4.3, 1.6 and 3.6-fold more resistant than SK-MES-1 (data taken from Table  II ). The ratios (A549:SK-MES-1) of total drug levels at 90 min are however 0.8, 1.3 and 1.7 in the absence of verapamil for ADR, VC and VP16 respectively. Table VI summarises the data obtained in the drug uptake experiments and enables a comparison of this data with the effect of verapamil on cytotoxicity. For VC verapamil produced major increases in both cytotoxicity and drug accumulation. Furthermore for SK-MES-1 the increases produced by verapamil on cytotoxicity, drug accumulation and drug 
Discussion
We have examined the sensitivity of a panel of 7 non-small cell lung cancer cell lines to 7 cytotoxic drugs. None of the cell lines (4 adenocarcinomas, 2 squamous carcinomas and 1 bronchiolo-alveolar carcinoma) had been exposed to cytotoxic drugs in vitro. A pattern of cross-resistance (termed pleiotropic drug resistance, PDR) to ADR, VC and VP16 was found similar to that described in animal models (for review see Kaye & Merry, 1985) . PDR has also been described in human haemopoietic tumour cell lines (Beck, 1983) , human glioma cell lines (Merry et al., 1984) and human small cell lung cancer cell lines (Shoemaker et al., 1983) . The cross-resistance data described here thus provide further evidence that PDR may be a general phenomenon in cell lines derived from human tumours, although the clinical relevance of PDR still remains to be established. PDR has two important characteristics; (a) altered membrane transport (possibly enhanced drug efflux) has been postulated as the major factor underlying this resistance and (b) in some experimental models PDR has been circumvented by calcium antagonists such as verapamil (for review see Chabner et al., 1983) .
We have studied the effect of 6.6 IM verapamil on the cytotoxicity of ADR, VC and VP16 in 5 cell lines. This dose of verapamil has been previously used to potentiate the effects of ADR and VC in human haemopoietic tumour cell lines (Tsuruo et al., 1983a) and of ADR in human ovarian tumour cell lines (Rogan et al., 1984) . This non-cytotoxic concentration of verapamil was able to potentiate the effect of the 3 cytotoxic drugs in some of the cell lines (up to 29-fold) with, particularly for ADR and VP16, potentiation in the most resistant cell lines.
Plasma levels of up to 1O pM verapamil may be achieved clinically by i.v. infusion , but these are associated with significant cardiovascular toxicity. Levels of 1-3 JM verapamil may be achieved in cancer patients using a daily oral dose of 480mg per day (Kerr et al., 1986) (Merry et al., 1986b (Table VI) . This suggests that (at least in these two cell lines) the major mechanism by which verapamil increases cytotoxicity to VC may be by influencing drug transport and/or binding. For ADR and VP16 smaller increases in drug accumulation were seen. These increases are associated with increased sensitivity to ADR (in both cell lines) and VP16 (in A549). In SK-MES-1, however, verapamil increased VP16 accumulation, but had no effect on cytotoxicity. Drug accumulation may not be rate-limiting for cytotoxicity in this particular case due to saturation of the intracellular binding sites at which VP16 acts.
In previous study (Merry et al., 1986a ) using human glioma cell lines verapamil (13 JM) produced increases in ADR uptake, binding and sensitivity in resistant cell lines. The increases were of equivalent size to those seen in this study.
Verapamil might also be enhancing drug sensitivity by a mechanism or mechanisms unrelated to total intracellular drug accumulation and binding. The presence of additional mechanisms of resistance is indicated by the observation that for VC and VP16 the drug sensitivity data (Table II) show A549 to be respectively 1.6 and 3.6-fold more resistant than SK-MES-1 while in the drug uptake experiments (Table VI) accumulation of drug was greatest in A549.
While in this study reduced ADR accumulation was noted in A549 (resistant) compared to SK-MES-1 (sensitive) a lack of correlation between sensitivity and uptake has been reported for rodent pancreatic carcinoma cell lines (Chang & Gregory, 1985) and human glioma cell lines (Merry et al., 1986a) . Kessel and Wilbarding (1985) have also reported that differences in ADR sensitivity between 2 sublines of P388 muring leukaemia could not be totally accounted for by differences in drug accumulation.
It is also recognised that clinical resistance to cytotoxic drugs may occur in tumours by mechanisms not involving biochemical changes within individual tumour cells. Examples of such mechanisms might be a reduction in tumour blood supply (leading to decreased entry of cytotoxic drug into the tumour) or increased cytotoxic drug degradation at a site other than the tumour (e.g. the liver). Such factors may also occur in combination with cellular factors. Nevertheless studies in several human solid tumour types have shown that the occurrence of drug resistance in the clinic is associated with the presence of drug-resistant clonogenic cells in biopsy specimens (Salmon, 1984) . These obser-vations indicate that resistance due to cellular mechanisms may be an important factor in clinically observed drug resistance.
In conclusion our data form part of a growing body of evidence that resistance to ADR, VC and VP16 may be multifactoral in nature, but suggest that (particularly for VC) changes in drug transport may be involved in resistance to these drugs in human solid tumours.
We have shown that verapamil is able to circumvent drug resistance in some human non-small cell lung cancer cell lines and that this effect (for VP16) can be demonstrated at clinically achievable plasma concentrations. Clinical studies using the approach of cytotoxic drug enhancement by noncytotoxic membrane-active compounds such as verapamil appear to be justified.
